NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National ...
The American Journal of Managed Care

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring ...
Targeted Oncology

NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Nasdaq

Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...
News Medical

Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of ...

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York ...
Nasdaq

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...
Medscape

Can New Biomarker Help Identify High-Risk DLBCL Patients?

For patients with diffuse large B-cell lymphoma (DLBCL), the detection of circulating tumor DNA (ctDNA) following first-line treatment is independently predictive of disease recurrence and overall ...